Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Osteoporosis Health Center

Font Size

Osteoporosis Drug May Fight Several Diseases

Study Shows Lasofoxifene Cuts Risk of Breast Cancer, Heart Attack, and Stroke
WebMD Health News
Reviewed by Louise Chang, MD

Feb. 24, 2010 -- A new entry in a popular class of osteoporosis drugs may help postmenopausal women reduce their risk of broken bones as well as fight breast cancer, heart disease, and stroke.

Lasofoxifene is a part of a class of drugs known as nonsteroidal selective estrogen-receptor modulators (SERMs). It has already been shown to decrease the bone loss and weakening associated with osteoporosis, like other SERMs, including tamoxifen and raloxifene. But until now its effect on other health conditions commonly experienced by postmenopausal women was unknown.

A new study shows that postmenopausal women with osteoporosis who took a 0.5-milligram daily dose of lasofoxifene had a 42% lower risk of vertebral (spinal) fractures and a 24% lower risk of non-vertebral fractures than those who took a placebo treatment.

The women who took lasofoxifene also had an 81% lower risk of estrogen-receptor (ER) positive breast cancer, a 32% lower risk of heart-related events like heart attack, and a 36% lower risk of stroke.

"This is the first SERM that reduces the risk of all of these conditions at once," researcher Steven Cummings, MD, of the San Francisco Coordinating Center at the California Pacific Medical Center Research Institute, says in a news release. "Not only did it reduce vertebral fractures, which was not unexpected, it also reduced the risk of non-vertebral fractures -- injuries to the arms, legs, ribs, hips -- that are the most common injuries to people with osteoporosis and the main causes of disability."

Although lasofoxifene is available in Europe, the FDA recently rejected a request for approval in the U.S., and some experts question whether its benefits surpass those of other SERMs already on the market.

Drug Fights Fractures and More

The study, published in the New England Journal of Medicine, followed 8,556 postmenopausal women with osteoporosis who were randomly assigned to receive either a 0.25-milligram or 0.5-milligram dose of lasofoxifene or a placebo over five years.

The results showed the 0.5-milligram dose was much more effective at lowering the risk of fractures and boosting bone density compared to the placebo.

Today on WebMD

Women working out and walking with weights
Reduce bone loss and build stronger muscles.
Chinese cabbage
Calcium-rich foods to add to your diet.
woman stretching
Get the facts on osteoporosis.
Porous bone
Causes, symptoms, risk factors, and treatment.
senior woman
Woman holding plate of brocolli
wrist xray
Superfood for Bones
mature woman
sunlight in hands
man and woman in front of xray
woman with dumbbells